GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Knight Therapeutics Inc (TSX:GUD) » Definitions » Price-to-Free-Cash-Flow

Knight Therapeutics (TSX:GUD) Price-to-Free-Cash-Flow : 24.22 (As of May. 05, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Knight Therapeutics Price-to-Free-Cash-Flow?

As of today (2024-05-05), Knight Therapeutics's share price is C$5.91. Knight Therapeutics's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 was C$0.24. Hence, Knight Therapeutics's Price-to-Free-Cash-Flow Ratio for today is 24.22.

The historical rank and industry rank for Knight Therapeutics's Price-to-Free-Cash-Flow or its related term are showing as below:

TSX:GUD' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 21.6   Med: 72.52   Max: 2790
Current: 24.22

During the past 11 years, Knight Therapeutics's highest Price-to-Free-Cash-Flow Ratio was 2790.00. The lowest was 21.60. And the median was 72.52.

TSX:GUD's Price-to-Free-Cash-Flow is ranked worse than
52.52% of 497 companies
in the Drug Manufacturers industry
Industry Median: 22.61 vs TSX:GUD: 24.22

Knight Therapeutics's Free Cash Flow per Share for the three months ended in Dec. 2023 was C$0.16. Its Free Cash Flow per Share for the trailing twelve months (TTM) ended in was C$0.24.

During the past 12 months, the average Free Cash Flow per Share Growth Rate of Knight Therapeutics was 44.90% per year.

During the past 11 years, Knight Therapeutics's highest 3-Year average Free Cash Flow per Share Growth Rate was 140.50% per year. The lowest was -178.20% per year. And the median was 49.60% per year.


Knight Therapeutics Price-to-Free-Cash-Flow Historical Data

The historical data trend for Knight Therapeutics's Price-to-Free-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Knight Therapeutics Price-to-Free-Cash-Flow Chart

Knight Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Free-Cash-Flow
Get a 7-Day Free Trial Premium Member Only Premium Member Only 631.67 - - 31.02 21.45

Knight Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Price-to-Free-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 31.02 258.82 109.78 51.14 21.45

Competitive Comparison of Knight Therapeutics's Price-to-Free-Cash-Flow

For the Drug Manufacturers - Specialty & Generic subindustry, Knight Therapeutics's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Knight Therapeutics's Price-to-Free-Cash-Flow Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Knight Therapeutics's Price-to-Free-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Knight Therapeutics's Price-to-Free-Cash-Flow falls into.



Knight Therapeutics Price-to-Free-Cash-Flow Calculation

Knight Therapeutics's Price-to-Free-Cash-Flow ratio for today is calculated as

Price-to-Free-Cash-Flow Ratio=Share Price/ Free Cash Flow per Share (TTM)
=5.91/0.244
=24.22

Knight Therapeutics's Share Price of today is C$5.91.
Knight Therapeutics's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was C$0.24.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

Price-to-Free-Cash-Flow Ratio=Market Cap/Free Cash Flow

Knight Therapeutics  (TSX:GUD) Price-to-Free-Cash-Flow Explanation

Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.

In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.


Be Aware

In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.


Knight Therapeutics Price-to-Free-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Knight Therapeutics's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


Knight Therapeutics (TSX:GUD) Business Description

Traded in Other Exchanges
Address
3400 De Maisonneuve West, Suite 1055, Montreal, QC, CAN, H3Z 3B8
Knight Therapeutics Inc is a specialty and generic drug manufacturing company. The company's principal business activity is focused on developing, acquiring, in-licensing, out-licensing, marketing, and distributing pharmaceutical products, consumer health products, and medical devices in Canada, Ltin America and select international markets. Knight finances other life sciences companies across the globe in order to generate interest income, strengthen relationships in the life sciences industry, and to secure product distribution rights.
Executives
Sime Armoyan 10% Security Holder

Knight Therapeutics (TSX:GUD) Headlines

No Headlines